MedTrace Logo

Safety Study of Oral BTA9881 to Treat RSV Infection

NCT00504907 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2018-05-30

No results posted yet for this study

Summary

This is a placebo-controlled, double-blind, randomised, single dose escalation Phase I clinical trial to determine the safety and tolerability of BTA9881 administered orally to healthy subjects

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

DRUG

BTA9881

Single oral escalating doses

DRUG

Placebo

Sponsors & Collaborators

  • Biota Scientific Management Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Peter Hodsman, MD · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504907 on ClinicalTrials.gov